Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia
Our study findings have demonstrated the efficacy of CLL1 CAR-T therapy in the treatment of AML patients with EMDs, while also indicating manageable occurrence rates of complications within a tolerable range. The CLL1 CAR-T therapy, serving as an ideal strategy for AML patients irrespective of the presence of EMDs, effectively ameliorates the conditions of AML patients and provides them with an opportunity to undergo curative hematopoietic stem cell transplantation while significantly enhancing their prognosis.
Authors
- Jile Liu
- Mingfeng Zhao (ORCID: https://orcid.org/0000-0002-5995-7558)
- Yifan Zhao (ORCID: https://orcid.org/0000-0003-1011-395X)
- Tianle Xie (ORCID: https://orcid.org/0009-0007-6298-1106)
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0002-6530-3825)
- Yu Zhang (ORCID: https://orcid.org/0000-0001-9317-2466)
- Xiaoyuan He
- Shujing Guo (ORCID: https://orcid.org/0009-0009-4092-8181)
- Xue Bai (ORCID: https://orcid.org/0000-0001-5725-2442)
- Mohan Zhao
- Haotian Meng
Institutions
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1186/s12967-024-05705-7
- Citations
- 16
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Tianjin Science and Technology Committee